Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Sweden / NCT07145567
Recruiting Observational

Microangiopathy in Diabetes

NCT07145567 · tracked via the Priya Life Science Sweden tracker
Sponsor
Karolinska Institutet
Phase
Observational
Started
2024-03-01
Last updated
2025-08-28

Condition(s) studied

MicroangiopathyMicrovascular Complications

Study summary

This clinical trial aims to evaluate the use of a contactless and non-invasive technique to measure the properties of the skin's microcirculation and its regulatory functions in both healthy individuals and patients with microvascular disease associated with type 1 diabetes. It is hoped that the study results will lead to the development of a useful method for detecting diabetic complications at an early stage, thereby enabling treatment and preventive measures before the onset of severe microangiopathy.

Eligibility

Sex
ALL
Min age
18 Years
Max age
60 Years
Healthy volunteers
Accepted
Inclusion Criteria: * Diabetes mellitus type 1. * Cohort specific inclusion criteria apply, please review 'groups' section. Exclusion Criteria: * Patients unable to understand patient information due to cognitive impairment. * Patients unable to understand patient information due to language barriers. * Ongoing acute infection disease or inflammatory condition. * Pregnant or breast-feeding women. * Patients with damaged and/or scarred tissue in the areas of interest for the investigational or comparator devices.

Primary outcome measure(s)

  • Peak perfusion in response to local thermal hyperemia — Investigation will take within 1 day from enrollment.
    As measured with investigational devices TCI P4, Pericam LSCI and EPOS devices.

Trial sites (1)

FacilityCityRegionStatus
Danderyd University Hospital Danderyd Stockholm County Recruiting

More Karolinska Institutet trials in Sweden

Effects of Individual Tailored Physical Exercise in Patients With POTS After COVID-19 - a Randomized Controlled Study Active, not recruiting
Implementation of Evidence-based Guidelines for Assessment and Counseling of Patients With Neck and Back Pain in Health Care Centers Starting soon
Single Nuclei Sequencing in Human Skeletal Muscle After Unloading Enrolling by invitation
Validation of a Novel Smartphone-based Method for Heart Rhythm Monitoring in the Home Environment Active, not recruiting
Omission of Axillary Lymph Node Dissection in Case of Tumor Spread to Lymph Nodes in the Armpit in Breast Cancer Recruiting

Other trials for the same condition

Non-invasive Microvascular Assessment in Individuals at High Risk of Cardiovascular Disease From the SCAPIS2 Study Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07145567 on ClinicalTrials.gov ↗ ← All trials in Sweden